Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

An update on the drug safety of treating erectile dysfunction

Research output: Contribution to journalReviewpeer-review

  1. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia

    Research output: Contribution to journalReviewpeer-review

  2. Cardiovascular safety and benefits of GLP-1 receptor agonists

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Parental Acceptance Rate of Testicular Tissue Cryopreservation in Danish Boys with Cryptorchidism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A qualitative analysis of Internet forum discussions on hard flaccid syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Surrogate testes: Allogeneic spermatogonial stem cell transplantation within an encapsulation device may restore male fertility

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Review of injection techniques for spermatogonial stem cell transplantation

    Research output: Contribution to journalReviewpeer-review

View graph of relations

Introduction: Treatment options for erectile dysfunction (ED) have evolved over the last two decades, particularly after the introduction of phosphodiesterase type-5 inhibitors (PDE5Is). The path, however, has not been straightforward with issues raised regarding safety and toxicity following ED treatments. Areas covered: A literature review was conducted on current evidence related to the safety of PDE5Is, intracavernosal injections and various older forms of oral therapies. Relevant trials were identified through a literature search of PubMed from 1980 to 2019. Expert opinion: PDE5Is are now recommended as the first line therapy for the treatment of ED due to their efficacy and tolerable side effects. Comparison of the various PDE5Is on safety has not been supported by prime evidence, and consequently, the negative aspects of each inhibitor appear the same as defined in the literature. Other means of therapies for ED are still in the running, and these also present a different range of side effects. While intracavernosal injections have potential to cause priapism and penile fibrosis, intraurethral alprostadil may result in more systematic side effects. Alternative topical ED therapies are generally limited with their local side effects.

Original languageEnglish
JournalExpert Opinion on Drug Safety
Volume18
Issue number10
Pages (from-to)965-975
Number of pages11
ISSN1474-0338
DOIs
Publication statusPublished - Oct 2019

    Research areas

  • Alprostadil/administration & dosage, Animals, Erectile Dysfunction/drug therapy, Fibrosis/chemically induced, Humans, Injections, Male, Penile Diseases/chemically induced, Phosphodiesterase 5 Inhibitors/administration & dosage, Priapism/chemically induced, Vasodilator Agents/administration & dosage

ID: 59046087